36 results about "Fetal tissue" patented technology

This invention provides a method for deriving precursors to pluripotent non-embryonic stem (P-PNES) and pluripotent non-embryonic stem (PNES) cell lines. The present invention involves nuclear transfer of genetic material from a somatic cell into an enucleated, zona pellucida free human ooplastoid having a reduced amount of total cytoplasm. The present invention provides a new source for obtaining human and other animal pluripotent stem cells. The source utilizes as starting materials an oocyte and a somatic cell as the starting materials but does not require the use, creation and/or destruction of embryos or fetal tissue and does not in any way involve creating a cloned being. The oocyte never becomes fertilized and never develops into an embryo. Rather, portions of the oocyte cytoplasm are extracted and combined with the nuclear material of individual mature somatic cells in a manner that precludes embryo formation. Murine, bovine, and human examples of the procedure are demonstrated. Subsequently, the newly constructed P-PNES cells are cultured in vitro and give rise to PNES cells and cell colonies. Methods are described for culturing the P-PNES cells to yield purified PNES cells which have the ability to differentiate into cells derived from mesoderm, endoderm, and ectoderm germ layers. Methods are described for maintaining and proliferating PNES cells in culture in an undifferentiated state. Methods and results are described for analysis and validation of pluripotency of PNES cells including cell morphology, cell surface markers, pluripotent tumor development in SCID mouse, karyotyping, immortality in in vitro culture.

<heading lvl="0">Abstract of Disclosure</heading> A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue, particularly fetal or neo-natal tissue, to chemical and mechanical processing. The process includes, but is not limited t, harvesting the tissue, optionally extracting growth and differentiation factors from the tissue, inactivating infective agents of the tissue, mechanically expressig undesirable components frm the tissue, delipidizing the tissue, washing the tissue, optionally drying the tissue, and optionally cross-linking the tissue not necessarily in the order described. The resulting product, EBM, is characterized by its microbial, fungal, viral and prion inactivated state. EBM is storng, bioremodelable, drapable and does not undergo calicification. EBM supplants previous inventions because of its unique method of preparation and broad applicability in tissue reengineering

Factors affecting the fragmentation pattern of cell-free DNA (e.g., plasma DNA) and the applications, including those in molecular diagnostics, of the analysis of cell-free DNA fragmentation patterns are described. Various applications can use a property of a fragmentation pattern to determine a proportional contribution of a particular tissue type, to determine a genotype of a particular tissue type (e.g., fetal tissue in a maternal sample or tumor tissue in a sample from a cancer patient), and/or to identify preferred ending positions for a particular tissue type, which may then be used to determine a proportional contribution of a particular tissue type.

A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue to chemical and mechanical processing. In addition to skin tissue, another source of EBM is a blood vessel. EBM may be used for hernia repair, colon, rectal, vaginal and or urethral prolapse treatment; pelvic floor reconstruction; muscle flap reinforcement; lung tissue support; rotator cuff repair or replacement; periosteum replacement; dura repair; pericardial membrane repair; soft tissue augmentation; intervertebral disk repair; and periodontal repair. EBM may also be used as a urethral sling, laminectomy barrier or spinal fusion device.

The invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. The fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion.

The invention also contemplates a method for treating a metabolic disorder, such as HPP, in a fetus or embryo were a protein is administered to a pregnant mother. The fusion protein comprises a Fc fragment of an IgG1 antibody peptide-bonded to TNSALP. The protein crosses the placenta of the mother and enters the fetal blood stream. The protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.

The invention relates to a method of making pluripotent stem cells that does not involve the formation of early preimplantation embryos or fetal tissue. The method has general utility in the production of pluripotent stem cells from many mammalian species but has particular application in man where pluripotent stem cell production can be customized to particular human individual. The method involves the fusion of donor somatic or stem cells (or their karyoplasts) with cytoplasmic, membrane-delimited fragments of mammalian oocytes or zygotes. After the initial genomic reprogramming occurs, the cells can proliferate and thus multiply in vitro yielding a large number of autologous cells for cell therapy application. The result of this process is a cell population genomically identical to the somatic, differentiated cells derived from an individual patient. However, these cells are pluripotent in that upon application of specific growth factors, the cells are capable of differentiating into specific cell types as required by the sought clinical indication.

The present invention provides a reference product for non-invasive prenatal detection of fetal aneuploid chromosomes. The reference product comprises: a first fragmented nucleic acid derived from thetissue of a maternal body having normal chromosome ploidy or the cultured cell line genome, and a second fragmented nucleic acid derived from the tissue or the cultured cell line genome of a fetus with positive chromosome aneuploidy, wherein the first fragmented nucleic acid is genetically related to the second fragmented nucleic acid, the first fragmented nucleic acid at least accounts for 70% of the total nucleic acid amount of the reference product, and the second fragmented nucleic acid accounts for 5-30% of the total nucleic acid amount of the reference product. According to the presentinvention, the reference product is easy to prepare, meets clinical practical demands, is used for the research and development and quality control on non-invasive prenatal detection related products,and has important application prospects.

A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 13 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Cells obtained in this way can be differentiated for use in treating conditions of cell damage, by supplanting the function of a damaged cell in a condition such as spinal cord injury, cardiovascular injury or heart disease.

The invention relates to a method for identifying a chromosome insertion translocation carried embryo and a normal embryo, belongs to the field of genetic diagnosis and human assisted reproduction, and particularly relates to an embryo pre-implantation detection technology (PGT). According to the method disclosed by the invention, family haplotype linkage analysis is carried out on a patient with chromosome balance insertion translocation and a partner thereof, an embryo after in-vitro insemination, relatives of a translocation carrier or fetal tissues with abnormal insertion fragments or chromosomes of an embryo with abnormal insertion fragments; the method can quickly, simply and accurately distinguish embryos with chromosomes inserted and translocated from embryos with normal chromosomes and screen chromosome aneuploidy of the embryos at the same time, so that diseased embryos and non-diseased embryos are detected in time before embryo transplantation, and defective children are prevented from birth; and the genetic transmission from chromosome insertion translocation to the next generation is blocked in time before embryo transplantation. The development and progress of a human assisted reproduction technology are promoted to a certain extent.

The invention belongs to the field of genetic diagnosis and human assisted reproduction, and particularly relates to a genetic detection technology (PGT) before embryo implantation. According to the method disclosed by the invention, family haplotype linkage analysis is carried out on a patient with the occult balance translocation of the chromosome, a partner of the patient, an embryo after in-vitro insemination, relatives of a translocation carrier or fetal tissues with abnormal translocation fragments, so that a translocation fragment monomer or trisome in the embryo of the occult balance translocation carrier can be simply, conveniently and accurately detected; the method has important clinical significance on embryo detection and birth defect prevention, and promotes the development and progress of human assisted reproduction technology to a certain extent.

The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair.

The invention relates to a method for quickly and efficiently extracting a macromolecular compound from sheep embryonic cells. The method mainly comprises two parts of contents. The core technical content I is that: fetal tissue cells are quick-frozen by liquid nitrogen, the obtained product is dried, and the obtained product is subjected to primary treatment by using a low-temperature ultrafine grinder; and the core technical content II is that: tissue cell precipitates and molecular complexes are gradually separated by using a method of carrying out centrifugation with different centrifugal speeds, and molecular peptide substances in cells are released to the maximum extent by combining ultrahigh-pressure cell crusher and low-temperature ultrasonic cell crusher treatment technologies. By the method, compound sheep placenta containing macromolecular and micromolecular peptides and the like can be obtained, natural active ingredients in the sheep embryonic cells are reserved to the maximum extent, the whole operation needs short time and is carried out under a low-temperature condition, the influence of temperature and time on the active ingredients such as the micromolecular peptide and the like in the extraction process is guaranteed to the maximum extent, and no any chemical reagent is added in the extraction process, so that the product obtained in the invention has better biological functions than a product obtained in the prior art.

The invention relates to a device for isolating stem cells from fetal tissues, which device has an incubation chamber, at least one pump, at least one reservoir for a tissue break-down solution, at least one reservoir for a rinsing solution, optionally a control unit, optionally a means for removing contaminants, and optionally a means for expansion of the isolated stem cells. The invention further relates to a method for isolating stem cells from fetal tissue, which method comprises, among other things, the mechanical dissociation and the enzymatic digestion of the fetal tissue and optionally density gradient centrifugation for removing contaminants. The device and the method according to the invention are particularly suitable for isolating mesenchymal stem cells from fetal tissues, such as umbilical cord tissue, placenta tissue, or fetal lung tissue.